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Summary
Tuberous sclerosis (TSC [MIM 191090 and MIM
191100]) is an autosomal dominant disorder character-
ized by hamartomas in many organs. Two thirds of cases
are sporadic and are thought to represent new muta-
tions. TSC is caused by mutations affecting either of the
presumed tumor-suppressor genes, TSC1 and TSC2.
Both appear to function as tumor suppressors, because
somatic loss or intragenic mutation of the corresponding
wild-type allele is seen in the associated hamartomas.
Here we report the first comprehensivemutation analysis
of TSC1 and TSC2 in a cohort of 150 unrelated TSC
patients and their families, using heteroduplex and SSCP
analysis of all coding exons and using pulsed-field gel
electrophoresis and conventional Southern blot analysis
and long PCR to screen for large rearrangements. Mu-
tations were characterized in 120 (80%) of the 150
cases, affecting TSC1 in 22 cases and TSC2 in 98 cases.
TSC1 mutations were significantly underrepresented in
sporadic cases ( ). Twenty-two patients hadP  .000185
TSC2 missense mutations that were found predomi-
nantly in the GAP-related domain (eight cases) and in a
small region encoded in exons 16 and 17, between nu-
cleotides 1849 and 1859 (eight cases), consistent with
the presence of residues performing key functions at
these sites. In contrast, all TSC1 mutations were pre-
dicted to be truncating, consistent with a structural or
adapter role for the encoded protein. Intellectual disa-
bility was significantly more frequent in TSC2 sporadic
cases than in TSC1 sporadic cases ( ). TheseP  .0145
data provide the first representative picture of the dis-
tribution and spectrum of mutations across the TSC1
and TSC2 loci in clinically ascertained TSC and support
a difference in severity of TSC1- and TSC2-associated
disease.
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Introduction
Tuberous sclerosis (TSC [MIM 191090 and MIM
191100]) is a disorder characterized by hamartomatous
involvement of many organs (Gomez 1988) and is es-
timated to affect 1/10,000 live births (Osborne et al.
1991). It is inherited as an autosomal dominant trait,
but 60%–70% of cases are sporadic and are thought to
represent new mutations (Fleury et al. 1980; Sampson
et al. 1989). The phenotype is highly variable. The brain,
skin, kidneys, and heart are all involved frequently, the
lungs, skeleton, endocrine glands, and most other organs
occasionally (Gomez 1988). Traditional diagnosis has
been based on combinations of clinical, radiological, and
histopathological signs; the criteria for definite diagnosis
have been revised recently and have become more strin-
gent than before (Roach et al. 1998). Significant and
common medical complications include epilepsy (75%),
intellectual disability (50%), and behavioral problems
(including autism and attention-deficit disorder with hy-
peractivity, in 40% of children). Penetrance is very high,
and the only cases of apparent nonpenetrance reported
after rigorous clinical evaluation have been recently dis-
proved by molecular genetic analysis (Young et al.
1998).
Two TSC-determining genes have been identified by
positional cloning—TSC1 at 9q34 (van Slegtenhorst et
al. 1997) and TSC2 at 16p13.3 (European Chromosome
16 Tuberous Sclerosis Consortium 1993). Molecular ge-
netic analysis of hamartomatous and occasional malig-
nant growths from patients with tuberous sclerosis have
revealed loss of heterozygosity or truncating intragenic
mutations affecting the corresponding wild-type allele
(Henske et al. 1996; Sepp et al. 1996; van Slegtenhorst
et al. 1997), indicating that TSC1 and TSC2 act as tumor
suppressors, as defined by Knudson (1971). The tumor-
suppressing properties of TSC2 have now been dem-
onstrated directly by transgenic expression in the Eker
rat, a naturally occurring model in which the homolo-
gous Tsc2 gene is mutated (Kobayashi et al. 1997). The
mechanisms through which TSC1 and TSC2 mediate
cellular growth control have been only partially eluci-
dated. Exons 34–38 of TSC2 encode a GTPase-activat-
1306 Am. J. Hum. Genet. 64:1305–1315, 1999
ing protein (GAP)–related domain having significant
homology to the GAPs rap1GAP and murine Spa1
(Maheshwar et al. 1996). Tuberin, the TSC2 product,
possesses modest GAP activity for rap1 (Wienecke et al.
1995) and rab5 (Xiao et al. 1997). These members of
the Ras superfamily of GTPases serve roles in mitoge-
nesis (Altschuler and Ribeiro Neto 1998), neuronal dif-
ferentiation (York et al. 1998), and early endosome fu-
sion (Gorvel et al. 1991). Tuberin also appears to play
a role both in cyclin-dependent kinase (CDK)–dependent
regulation of transition from G0/G1 to S phase during
the cell cycle (Soucek et al. 1997) and in neuronal dif-
ferentiation (Soucek et al. 1998). Specific cellular roles
have not yet been reported for hamartin, the TSC1 prod-
uct, but hamartin and tuberin have been shown to coim-
munoprecipitate, interact in the yeast two-hybrid sys-
tem, and colocalize on immunofluorescence (Plank et al.
1998; van Slegtenhorst et al. 1998), suggesting that the
proteins participate in at least some common pathways.
Mutation analysis of both TSC1 and TSC2 has not
been reported previously in a series of patients with TSC.
Comprehensive analysis of TSC2 has been frustrated
both by the size and structure of the gene (i.e., 41 coding
exons and 1 leader exon) and because, until very re-
cently, the full genomic sequence has not been available.
There are several reports of single or small numbers of
TSC2 mutations identified during incomplete screening
of the gene (Kumar et al. 1995a, 1995b, 1997; Vrtel et
al. 1996; Jobert et al. 1997; Verhoef et al. 1998; Wang
et al. 1998). Three studies have attempted more com-
plete analysis of TSC2. Wilson et al. (1996) have used
single-strand conformation polymorphism (SSCP) anal-
ysis of reverse-transcriptase–PCR products to study 30
unrelated probands and have reported nine possible mu-
tations. One mutation, DF1509, has subsequently been
seen in unaffected controls and is believed to be non-
pathogenic (Jones et al. 1997). The pathogenicity of sev-
eral missense changes identified in that study remains
unconfirmed. van Bakel et al. (1997) have used the pro-
tein-truncation test to study 18 unrelated patients and
have identified truncating mutations in 5 of them. Au
et al. (1998) have used SSCP analysis of all coding exons
to study 90 unrelated cases and have identified 22 pu-
tative mutations. In addition, several studies have been
made of patients with TSC and severe polycystic kidney
disease, most of whom appear to have a contiguous
gene–deletion syndrome involving TSC2 and the adja-
cent autosomal dominant polycystic kidney disease type
1 gene, PKD1 (Brook-Carter et al. 1994; Longa et al.
1997; Sampson et al. 1997). Analysis of the TSC1 gene
has proved more straightforward. The complete genomic
sequence of TSC1 was established when the gene was
identified. It is significantly less complex than TSC2,
comprising 21 coding and 2 leader exons. At least five
systematic studies of TSC1 mutations have been re-
ported (Jones et al. 1997; Ali et al. 1998; Kwiatkowska
et al. 1998; Young et al. 1998; van Slegtenhorst et al.,
in press); all identified TSC1 mutations in only 10% of
sporadic cases of TSC. It is therefore clear that previous
studies of TSC have failed to identify most of the caus-
ative mutations.
We set out to determine the distribution and nature
of TSC1 and TSC2 mutations in a large and represen-
tative series of patients and families with TSC. Knowl-
edge of these parameters is required both for develop-
ment of efficient molecular diagnosis and for studies of
the genotype-phenotype relationship. In previous studies
of this patient cohort, we have screened all coding exons
of the TSC1 gene and exons 1, 25, 31, 34–39, and 41
of the TSC2 gene, and we have searched for large-scale
rearrangements at the TSC1 and TSC2 loci (Jones et al.
1997; Maheshwar et al. 1997). To obtain comprehensive
data, we have completed SSCP and heteroduplex anal-
ysis of all TSC2 exons and, by means of Southern anal-
ysis and long PCR, have supplemented our previous
search for large rearrangements at both loci.
Patients and Methods
Patients
The study was approved by the ethics committee of
the Division of Medicine, South Glamorgan Health Au-
thority. The index cases comprised 150 consecutive un-
related patients with TSC who were listed with the In-
stitute of Medical Genetics, Cardiff, prior to April 1994
and for whom samples were available for comprehensive
analysis of the TSC1 and TSC2 genes. Patients specifi-
cally ascertained by us for a separate study of renal cystic
disease in TSC (Sampson et al. 1997) were not included,
but nine cases ascertained for other reasons who were
subsequently found to have polycystic kidneys were in-
cluded. Initially the series comprised 171 apparently un-
related patients, but 21 were excluded, 7 because they
failed to satisfy the recently revised criteria for diagnosis
of definite TSC (Roach et al. 1998), 13 because further
samples required for completion of the analysis were not
available, and, in 1 case, because previously unrecog-
nized kinship to another index case who carried the same
mutation was identified. Intellectual disability was con-
sidered to be present when formal developmental as-
sessment revealed a developmental quotient !70, when
unassisted mainstream schooling was impossible because
of intellectual disability (not behavioral problems), or
when an adult was institutionalized or required super-
vision in the community.
PCR
Genomic DNA was prepared from peripheral blood
samples by standard methods. PCR primers were de-
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signed with the aid of the “Oligo Analysis” software
package (Wojciech Rychlik). Primer sequences and an-
nealing temperatures for amplification of all TSC1 and
TSC2 coding exons and for long PCR at the TSC1 and
TSC2 loci are available at the Cardiff-Rotterdam Tu-
berous Sclerosis Mutation Database Website. Standard
PCR was done in 50-ml reaction volumes containing 100
ng of genomic DNA, 25 pmol of each primer, 0.2 mM
dNTP, 5 ml of reaction buffer (100 mM Tris pH 8.3,
500 mM KCl, 15 mM MgCl2, 0.01% gelatin), and 1 U
of AmpliTaq Gold Polymerase (Cetus). Cycling param-
eters were 94C for 10 min, followed by 32 or 33 cycles
of 54C–58C for 1 min, 72C for 1 min, and 94C for
30 s, and a final step of 72C for 10 min. Long PCR
was done in 50-ml reaction volumes containing 100 ng
of genomic DNA, 4 pmol of each primer, 0.35 mM
dNTP, 5 ml of Boehringer-Mannheim reaction buffer 3
(20 mM Tris -HCl, 100 mM KCl, 22.5 mM MgCl2, 1
mM DTT, 0.1 mM EDTA, 0.5% [v/v] Tween 20, 0.5%
[v/v] Nonidet P40, 50% [v/v] glycerol), and 2 U of
Expand Long Template polymerase (Boehringer Mann-
heim). Cycling parameters were 95C for 2 min, fol-
lowed by 28 cycles of 65C for 30 s, 68C for 8 min,
and 94C for 30 s. The elongation step was increased
by 20 s for each cycle after cycle 10.
SSCP and Heteroduplex Analysis
SSCP was done on 3 ml of PCR product diluted 1:10
with formaldehyde containing 0.0125% bromophenol
blue and 0.75% Ficoll 400. Samples were denatured at
94C for 5 min, snap-cooled on ice, and triple-loaded
(at 2-h intervals) on a mutation detection enhancement
(MDE) gel (Flowgen). Electrophoresis was done in
borate EDTA at 6 W for 18 h at room tem-0.6# Tris
perature. Heteroduplex analysis was performed by mix-
ing of 5-ml aliquots of two PCR products with 0.6 ml of
0.1 M EDTA, denaturing at 94C for 5 min, and then
slow cooling to 37C. One microliter of electrophoresis
dye (Hoefer) was added to each of the samples, which
were then quadruple-loaded (at 1-h intervals) on an
MDE gel and run at 4.5 W for 15 h at room temperature.
Products on SSCP and heteroduplex gels were visualized
by silver staining, as described elsewhere (Jones et al.
1997).
DNA Sequencing
PCR products of samples displaying variant banding
patterns were sequenced by means of either the Sequen-
ase PCR Product Sequencing kit or the Thermo-
Sequenase cycle sequencing kit (Amersham).
Southern Analysis
Genomic DNA for Southern analysis was digested
with EcoRI, HindIII, and BamHI, electrophoresed, and
blotted, as described elsewhere (Sampson et al. 1997),
and were probed with TSC1 and TSC2 cDNA clones.
Samples yielding variant restriction patterns were sub-
jected to further restriction analysis to characterize the
mutations involved. Products generated by long PCR
amplification were blotted to Hybond N. Amplified ex-
ons were used as probes to determine which were deleted
and which were preserved on the mutant chromosomes.
Microsatellite Analysis
Evidence for biological paternity and maternity in
cases with apparently de novo mutations was assessed
by means of highly polymorphic microsatellite repeats
on chromosomes 4 (D4S43), 6 (D6S250), 7 (D7S636),
15 (D15S945), and 16 (D16S665).
Mutation Nomenclature
Mutation nomenclature has been inconsistent at the
TSC2 locus, since the transcript initially reported by the
European Chromosome 16 Tuberous Sclerosis Consor-
tium (1993) did not contain the nucleotides correspond-
ing to exon 31, which is subject to alternative splicing
(Maheshwar et al. 1996). We numbered nucleotides ac-
cording to the full-length TSC1 and TSC2 cDNAs as in
GenBank (accession numbers AF013168 and X75621,
respectively), and mutations were described as recom-




Of the 150 index cases comprehensively screened for
TSC1 and TSC2 mutations, 130 were sporadic, 19 were
classified as familial (having an affected parent, with or
without other affected family members), and 1 patient
had been adopted and the clinical status of the biological
parents was unknown. At ascertainment, the total num-
ber of living affected individuals in the 150 families was
199, and the overall proportions of sporadic and familial
cases were 65% and 35%, respectively. Thirteen further
cases were screened by pulsed-field gel electrophoresis
(PFGE) and by SSCP and heteroduplex analysis of cod-
ing exons of TSC1 but, because of inadequate or de-
graded DNA samples, were not screened comprehen-
sively for mutations of TSC2.
Mutations at the TSC Loci
Likely disease-causing mutations were characterized
in 120 (80%) of the 150 index cases; of these 120 mu-
tations, 22 (18%) were at the TSC1 locus, and 98 (82%)
were at the TSC2 locus. In a previous study, we had
reported all but one of the TSC1 mutations (Jones et al.
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Table 1
TSC2 Nonsense, Frameshift, and Splice Mutations
Patient Location Mutation Nucleotide Change
Type of
Mutation
341 Exon 4 Y155X C483G Nonsense
291 Exon 4 485ins5bp 5-bp insertion Frameshift
046 Exon 5 546delC 1-bp deletion Frameshift
246 Intron 7 793-1GrA G793-1A Splice
024 Intron 11 12752TrC T12752C Splice
255 Intron 13a 1462-1GrA G1462-1A Splice
366 Exon 14 1506delC 1-bp deletion Frameshift
100 Exon 14 R505Xb C1531T Nonsense
159 Exon 14 R505X C1531T Nonsense
173 Exon 14 R505X C1531T Nonsense
017 Exon 16 Y598X C1812G Nonsense
289 Exon 16 1813delA 1-bp deletion Frameshift
222 Exon 18 1993del7bp 7-bp deletion Frameshift
090 Exon 18 2042del19bp 19-bp deletion Frameshift
081 Exon 18 2092delG 1-bp deletion Frameshift
310 Exon 19 W703X G2127A Nonsense
086 Exon 19 2160del16bp 16-bp deletion Frameshift
006 Exon 20 R751X C2269T Nonsense
054 Exon 20 R751X C2269T Nonsense
245 Exon 20 R751X C2269T Nonsense
238 Exon 20 2313insCC 2-bp insertion Frameshift
142 Intron 20 23732TrC T23732C Splice
134 Intron 20 23732del4bp 4-bp deletion Splice
158 Exon 21 Y790X C2388G Nonsense
235 Exon 21 2548delC 1-bp deletion Frameshift
317 Intron 24 28551GrT G28551T Splice
197 Exon 28 3414delG 1-bp deletion Frameshift
119 Exon 29 Q1148X C3460T Nonsense
166 Exon 29 Q1192X C3592T Nonsense
233 Exon 29 Q1192X C3592T Nonsense
015 Exon 30 3691ins5bp 5-bp insertion Frameshift
377 Exon 30 3713delC 1-bp deletion Frameshift
186 Exon 33 Q1419X C4273T Nonsense
001 Exon 33 S1433X C4316A Nonsense
027 Exon 33 R1459X C4393T Nonsense
040 Exon 33 R1459X C4393T Nonsense
240 Exon 33 R1459X C4393T Nonsense
373c Exon 34 4512insC 1-bp insertion Frameshift
147c Exon 34 4559del4bp 4-bp deletion Frameshift
234c Exon 35 4594del7bp 7-bp deletion Frameshift
093c Exon 35 4609delG 1-bp deletion Frameshift
230c Exon 36 Y1571X C4731G Nonsense
036c Exon 38 Q1665X C5011T Nonsense
248d Intron 38 5087-2ArG A5087-2G Splice
351d Exon 39 5178delTG 2-bp deletion Splice
229 Exon 40 5229del4bp 4-bp deletion Frameshift
018d Exon 41 5358del32bp 32-bp deletion Frameshift
357d Exon 41 5406insC 1-bp insertion Frameshift
172d Exon 41 5425insT 1-bp insertion Frameshift
a GrT has been observed in a patient reported by Jobert et al. (1997).
b Also observed in a patient reported by Wilson et al. (1996).
c Also reported by Maheshwar et al. (1997).
d Also reported by Jones et al. (1997).
1997). In that study, patient 365 with sporadic TSC was
shown to have the de novo TSC1 missense mutation
A726E. We have now also demonstrated a de novoTSC1
nonsense mutation W750X, Gr A at 2471, in this pa-
tient. The presence of both de novo mutations was con-
firmed through repeat samples, and biological par-
enthood was confirmed through five polymorphic mi-
crosatellite markers. The TSC2 mutations are summa-
rized in tables 1–3. With regard to the TSC2 locus, 22
patients had whole-exon, multiexon, or whole-gene de-
letions or other large rearrangements, 20 had nonsense
changes, 21 had small insertions or deletions predicted
to lead to both a change of reading frame and premature
truncation, 8 had changes in splice-site consensus se-
quences, 5 had in-frame deletions of one to six amino-
acid residues, and 22 had missense changes.
Evidence for pathogenicity of the TSC2 missense
changes and small in-frame deletions was obtained by
study of additional family members. Two small in-frame
deletions—DI365 (unique) and 5256del18bp (recur-
rent)—were shown to arise de novo in sporadic cases,
as were 11 of 14 different missense mutations. In all
these cases, results of analysis of five polymorphic mi-
crosatellite markers were consistent with biological
parenthood. A further unique missense change, G294E,
occurred in a familial case; its pathogenicity is uncon-
firmed. Segregation of the missense change with TSC in
this family has been demonstrated by others (A. Astrin-
idis and S. Povey, personal communication). Parental
samples were unavailable for two apparently sporadic
cases, 050 and 253, who carried the unique missense
changes C696Y and R1743P and in whom no other
TSC1 or TSC2 mutations were identified. The missense
mutations were located principally in the GAP-related
domain of TSC2 encoded in exons 34–38 and in a short
stretch of nucleotides at positions 1849–1859 (table 2
and fig. 1). Small truncating lesions were distributed
across the TSC1 and TSC2 genes (fig. 1).
Eight TSC2 mutations (tables 1 and 2) and one TSC1
mutation, CrT at 2577, R786X, were seen recurrently.
Together, these accounted for 28 (23%) of the 120 mu-
tations identified (i.e., 19% of the 150 index cases).
TSC1 and TSC2 Mutations in Familial and Sporadic
Cases
Of the 19 familial cases, 9 had TSC1 mutations and
9 had TSC2 mutations; no mutation was detected in 1
(5%) of the familial cases. Of the 130 sporadic cases,
13 had TSC1 mutations and 88 had TSC2 mutations;
no mutation was detected in 29 (22%) of the sporadic
cases. TSC1 mutations were therefore significantly un-
derrepresented among sporadic cases ( , 1 df;2x  13.975
). One adopted case with an unknown fam-P  .000185
ily history had a TSC2 mutation.
Germ-Line Mosaicism
In 1 of the 150 families studied, two affected siblings
had parents who were normal on clinical examination.
The TSC2 mutation R905W (CrT at 2731) was iden-
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Table 2
TSC2 Missense Mutations and In-Frame Deletions
Patient Exon Mutation Nucleotide Change Type of Mutation De Novo?
278 9 G294E G899A Missense Familial
060 10 DI365 1111del3bp In-frame deletion Yes
098 16 R611Wa C1849T Missense Not tested
208 16 R611W C1849T Missense Not tested
217 16 R611W C1849T Missense Yes
032 16 R611Qb G1850A Missense Yes
123 16 R611Q G1850A Missense Not tested
102 16 R611Q G1850A Missense Not tested
353 16 R611Q G1850A Missense Not tested
275 17 A614D C1859A Missense Yes
253 18 C696Y G2105A Missense Not tested
362 23 R905Wb C2731T Missense Yes
220 33 P1497R C4508G Missense Yes
211 33 S1498N G4511A Missense Yes
306c 36 L1594M C4798A Missense Yes
367c 37 N1643K C4947G Missense Yes
276c 37 N1651S A4970G Missense Yes
084c 38 P1675L C5042T Missense Not tested
241c 38 P1675L C5042T Missense Not tested
247c 38 P1675L C5042T Missense Not tested
302c 38 P1675L C5042T Missense Yes
223c 38 N1681K C5061G Missense Yes
311 40 5256del18bp 18-bp deletion In-frame deletion Not tested
003 40 5256del18bp 18-bp deletion In-frame deletion Not tested
044 40 5256del18bp 18-bp deletion In-frame deletion Yes
360 40 5256del18bp 18-bp deletion In-frame deletion Not tested
050 40 R1743P G5246C Missense Not tested
a Also reported by Wilson et al. (1996)
b Also reported by Au et al. (1998)
c Also reported by Maheshwar et al. (1997).
tified in the index case, patient 362, and in his affected
sibling but was not detected in DNA extracted from
leukocytes from each of the parents. Result of analysis
of five microsatellite markers were consistent with bio-
logical parenthood, suggesting the presence, in one of
the parents, of mosaicism involving the germ line for
this mutation.
Polymorphisms
Thirty-nine sequence variants likely to represent non-
pathogenic polymorphisms were observed at the TSC2
locus, both in TSC patients and in either normal controls
or TSC-family members without clinical or radiographic
evidence of TSC. Thirty of these have not been reported
previously unreported and are listed in table 4; they in-
clude nine missense variants within the coding region.
TSC1 polymorphisms have been reported elsewhere
(Jones et al. 1997).
Intellectual Disability
Intellectual disability was present in 86 (57%) of the
150 index cases and in 97 (49%) of the 199 affected
members in the 150 different families. Intellectual dis-
ability was significantly more common in sporadic cases
carrying TSC2 mutations (59 [67%] of 88 cases) than
sporadic cases carrying TSC1 mutations (4 [31%] of 13
cases) ( , Fisher’s exact test; odds ratio 4.5).P  .0145
The frequency of intellectual disability in sporadic cases
with TSC2 missense or small in-frame deletion muta-
tions (15 [68%] of 22 cases) was not significantly dif-
ferent from that in sporadic cases with other classes of
TSC2 mutations (44 [67%] of 66 cases) ( ,P  .506
Fisher’s exact test).
Unusual Somatic Features
Gross polycystic kidney disease was detected on ul-
trasound scan (but was not the presenting feature) in
nine cases. All of these cases had TSC2 mutations, and,
in six cases, these mutations were contiguous deletions
also involving the PKD1 gene. Four of the six cases
with TSC2/PKD1 deletions were somatic mosaics. Two
cases had large intragenic deletions affecting TSC2, and
one case had a 600-kb inversion disrupting TSC2 (table
3). All cases have been reported elsewhere (European
Chromosome 16 Tuberous Sclerosis Consortium 1993;
Brook-Carter et al. 1994; Sampson et al. 1997). Fifteen
of 22 index cases with TSC1 mutations had no evidence
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Table 3




002 Multigene deletion TSC2/OCTS3/OCTS2 PFGE Jones et al. (1997)
019 Intragenic deletion ≈5 kb Southern European Chromosome 16 Tuberous Sclerosis Consortium (1993)
022 Mosaic multigene deletion TSC2/PKD1 PFGE Sampson et al. (1997)
076 Multigene deletion TSC2/OCTS3/OCTS2 PFGE European Chromosome 16 Tuberous Sclerosis Consortium (1993)
0786 Multigene deletion TSC2/OCTS3/OCTS2 PFGE Brook-Carter et al. (1994)
080 Multigene deletion TSC2/OCTS3/OCTS2 PFGE European Chromosome 16 Tuberous Sclerosis Consortium (1993)
088 Intragenic deletion ≈10 kb PFGE Jones et al. (1997)
111 Mosaic multigene deletion TSC2/PKD1 PFGE Sampson et al. (1997)
136 Intragenic deletion ≈4 kb (exons 17–20) Long PCR Present study
148 Multigene deletion TSC2/OCTS3 Southern European Chromosome 16 Tuberous Sclerosis Consortium (1993)
179 Multigene deletion TSC2/PKD1 PFGE European Chromosome 16 Tuberous Sclerosis Consortium (1993)
180 Intragenic deletion ≈3 kb Southern European Chromosome 16 Tuberous Sclerosis Consortium (1993)
181 Multigene deletion TSC2/OCTS2/OCTS3 PFGE European Chromosome 16 Tuberous Sclerosis Consortium (1993)
206 Intragenic deletion ≈5 kb Southern Jones et al. (1997)
216 Intragenic deletion ≈1 kb (exons 37–38) Southern Jones et al. (1997)
270 Mosaic multigene deletion TSC2/PKD1 PFGE Sampson et al. (1997)
277 Intragenic deletion ≈3 kb (exon 11, part of exon 12) Long PCR Present study
283 Mosaic multigene deletion TSC2/PKD1 PFGE Sampson et al. (1997)
284 Multigene deletion TSC2/PKD1 PFGE Sampson et al. (1997)
308 Deletion of TSC2 and 3′ UTR of PKD1 Southern Sampson et al. (1997)
346 Intragenic deletion ≈8 kb (exons 3–8) Southern Present study
431 Inversion ≈600 kb PFGE Sampson et al. (1997)
of renal cysts on ultrasound scan. Three had unilateral
solitary cysts (at age 35, 50, and 64 years). No renal
ultrasound scan was performed in four cases with TSC1
mutations.
Three female patients had a history of pneumothorax
and either cystic or honeycomb changes in the lungs on
radiographic investigation, consistent with a diagnosis
of lymphangioleiomyomatosis (LAM). One case, patient
080, had a large deletion mutation involving both the
5′ end ofTSC2 and theOCTS3 andOCTS2 genes, which
lie immediately 5′ of TSC2. Another case, patient 208,
had the recurrent TSC2 missense change R611W. The
third case, patient 256, had bony sclerosis, with expan-
sion of the right clavicle, and asymmetry affecting the
right side of the face, in addition to cystic changes in
the right lung. This patient carried the TSC1 nonsense
change S334X. All of these cases were sporadic.
Localized overgrowth affecting the limbs was ob-
served in three female patients, all of whom otherwise
had typical multiorgan involvement. TSC2 mutations
were identified in DNA extracted from venous blood in
two of these patients. Patient 211, carrying the de novo
missense change S1498N, had massive overgrowth of
the right leg, involving the bones and soft tissues, that
progressed during infancy and childhood and that, at
age 30 years, led to amputation of the leg. Patient 046
carried the single-base deletion 546delC and had over-
growth localized to the left little finger. No mutation
was identified in the third case, who had overgrowth
affecting the bones and soft tissues of the left forearm
and of the middle and ring fingers.
Discussion
We studied 150 unrelated individuals with TSC, as
well as their family members. The proportions of familial
and sporadic cases among all 199 affected members of
their families were 35% and 65%, respectively, and the
overall frequency of intellectual disability was 49%.
These figures are similar to those reported in large ep-
idemiological studies (Sampson et al. 1989; Osborne et
al. 1991), suggesting that the present series is represen-
tative of clinically ascertained TSC. We identified mu-
tations in a total of 120 (80%) of these patients; 98
(65.4%) were shown to have mutations at the TSC2
locus, and 22 (14.6%) had mutations at the TSC1 locus.
One hundred one different mutations were characterized
(21 affecting TSC1 and 80 affecting TSC2), of which
42 had not been described previously. Mutations were
not identified in 1 of 19 familial cases or in 29 of 130
sporadic cases. Recent studies have shown that somatic
mosaicism may be a frequent finding among sporadic
cases of TSC (Sampson et al. 1997). The SSCP and het-
eroduplex analyses used for exon screening in this study
are unlikely to have had sufficient sensitivity to detect
low-level mosaicism, and they also have limited sensi-
tivity in the detection of some nonmosaic mutations.
These factors, as well as our incomplete assessment of
Figure 1 Distribution of point mutations and small deletions and insertions in the TSC1 and TSC2 genes. Numbered boxes denote individual exons.
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Table 4




Intron 3 35431CrT C35431T Unique
Exon 4 L160V C496G Unique
Intron 4 5003CrT C5003T 5%–10%
Intron 4 5007CCrAA CC5007AA Unique
Exon 8 R261W C799T Unique
Exon 9 M286V A874G !5%
Exon 10 R367Q G1118A !5%
Exon 10 Q370 A1128G !5%
Exon 11 P378L C1151T Unique
Exon 12 G440S G1336A Unique
Exon 13 G459 C1395T Unique
Exon 13 I463V A1405G Unique
Intron 14 161814CrT C161814T 5%–10%
Intron 14 161839CrT C161839T 5%–10%
Intron 15 173516CrT C173516T Unique
Exon 16 A583T G1765A !5%
Exon 18 P677 C2049T Unique
Intron 18 211535GrA G211535A Unique
Intron 22 265744CrG C265744G !5%
Intron 31 390178GrA G390178A 5%–10%
Intron 31 390251CrG C390251G !5%
Intron 31 390255ArT A390255T Unique
Exon 33 D1436 C4326T Unique
Intron 35 468143GrA G468143A Unique
Intron 39 51799ArC A51799C 5%–10%
Intron 39 517926delTGAG 4-bp deletion !5%
Intron 40 527773CrT C527773T Unique
Intron 40 527780CrT C527780T Unique
Exon 41 G1791S G5389A Unique
3′ UTR 5503delAA 2-bp deletion !5%
intronic and regulatory sequences, likely account for our
failure to detect mutations in 20% of the cases. Further
locus heterogeneity in TSC also remains a theoretical
possibility.
We found that significantly more of the sporadic cases
had TSC2 than had TSC1 mutations. This would be
expected if the germ-line mutation rate at theTSC2 locus
were higher than at the TSC1 locus. However, additional
familial TSC2 cases would also be expected, and we did
not observe this; nor has a significant excess of families
without linkage to TSC1 been observed in linkage stud-
ies (Sampson et al. 1991; Povey et al. 1994). A possible
explanation for the apparent excess of TSC2 mutations
among sporadic cases—but not among familial cases—
would be greater overall severity of TSC2-associated dis-
ease. We assessed the frequency of intellectual disability
in sporadic cases, as a reliable and important aspect of
disease severity. Unlike many other components of the
phenotype that show age-dependent penetrance, intel-
lectual disability in TSC is almost invariably present
from early childhood and rarely escapes detection. We
found intellectual disability to be significantly more fre-
quent among sporadic cases with TSC2 mutations than
among those with TSC1 mutations. If the presence or
absence of intellectual disability is, in part, related to
the frequency of “second hit” mutations in the devel-
oping brain, then our observations could reflect a so-
matic mutation rate that is higher at the TSC2 locus
than at the TSC1 locus. Alternatively, tuberin may serve
roles in the CNS that are not shared by hamartin.
Elsewhere, we have shown that most patients with
TSC and severe polycystic kidney disease have contig-
uous deletions involving TSC2 and the adjacent poly-
cystic kidney disease 1 (PKD1) gene (Brook-Carter et al.
1994; Sampson et al. 1997). The present series did not
include cases specifically ascertained because of poly-
cystic kidney disease, but polycystic kidney disease was
identified in 9 of the 150 index cases. Six of these cases
had TSC2-PKD1 deletions, of whom four were mosaics.
Deletion of TSC2 and of only the 3′ UTR of PKD1
was found in a further case, who did not have polycystic
kidneys. Three cases with polycystic kidneys had TSC2
mutations that did not involve PKD1. Solitary cysts—
but not polycystic kidneys—were seen in some patients
with TSC1 mutations. Specific study of a larger cohort
of patients is required in order to determine whether
TSC1 disease carries a risk of clinically significant renal
cystic disease.
Symptomatic cystic lung disease presenting as pneu-
mothorax was a feature in three cases in the present
series. Two patients with TSC2 mutations had wide-
spread honeycomb appearances in both lungs that was
typical of LAM, and the third, with a TSC1 mutation,
had marked cystic changes in the upper lobe of the right
lung. LAM is a disorder seen almost exclusively in fe-
males and is characterized by bronchiolar smooth-mus-
cle infiltration and cystic changes in the lung paren-
chyma. This is usually associated with angiomyolipoma
of the kidneys and/or abdominal and hilar lymph nodes.
Symptomatic LAM is estimated to occur in ∼1/million
of the population, without other evidence of TSC, but
in several percent of females with TSC, implicating a
role for the TSC genes in the etiology of LAM. Loss of
heterozygosity for markers in the TSC2 region has been
observed in renal angiomyolipomas and lymph nodes
removed from women with LAM but without other
signs of TSC (Smolarek et al. 1998), but mutations of
the TSC genes had not been reported previously in pa-
tients with either TSC-associated LAM or sporadic
LAM.
Studies of other components of the TSC phenotype in
TSC1- and TSC2-associated disease are now required,
particularly to quantify the frequency and severity of
complications. Given our findings in relation to the dis-
tribution of TSC1 and TSC2 mutations in sporadic and
familial cases, as well as the likelihood that familial cases
will be less severely affected than are sporadic cases, such
studies will have to be based on either sporadic cases or
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epidemiologically complete populations, or they will
have to employ valid corrections for ascertainment bias.
The large proportion of TSC2 mutations—as opposed
to TSC1 mutations—that we observed in medically as-
certained TSC has implications for the development of
molecular diagnostics. Not only is the TSC2 gene, in its
structure, substantially more complex than the TSC1
gene, but we have also found its mutational spectrum
to be more diverse. Several studies have found the great
majority of germ-line mutations at the TSC1 locus to be
small truncating lesions (Jones et al. 1997; Ali et al.
1998; Kwiatkowska et al. 1998; Young et al. 1998; van
Slegtenhorst et al., in press). In contrast, we have now
shown that, at the TSC2 locus, missense changes, large
rearrangements including whole-gene deletions, non-
sense mutations, and small insertions and deletions are
represented at similar frequencies. The sensitivity of any
single currently available approach for mutation detec-
tion at the TSC2 locus is therefore likely to be limited.
However, we did observe eight TSC2 mutations recur-
rently, at least three of which (R505X, R611W, and
R611Q) have also been reported by other investigators
(Wilson et al. 1996; van den Ouweland et al. 1997; Au
et al. 1998). Seven of the mutations seen recurrently were
due to CrT or GrA substitutions at CpG dinucleotides
and are likely to result from spontaneous deamination
of methylated cytosines in the genomic DNA. The in-
frame TSC2 deletion, 5256del18bp, was identified in
four unrelated sporadic cases. It involves a direct repeat
of 11 nucleotides and the intervening 7 nucleotides and
is likely to be the result of slipped mispairing during
replication (Cooper and Krawczak 1993). Several TSC1
mutations also have been seen recurrently (Jones et al.
1997; van Slegthenhorst et al. 1997, and in press; Ali et
al. 1998; Kwiatkowska et al. 1998; Young et al. 1998),
suggesting that assay for a small number of TSC2 and
TSC1 mutations might provide a useful initial screen in
the diagnostic setting.
Our characterization of significant numbers of mis-
sense mutations and some small in-frame deletions at
the TSC2 locus is likely to be helpful in the investigation
of putative functions of the gene product. The effects
that the missense changes in the GAP-related domain
have on GAP activity toward rap1 and rab5 are now
under investigation, as is the effect that the single-residue
deletion DI365 has on the binding of hamartin by tub-
erin. Natural mutants of this kind may prove useful for
determination of which of tuberin’s functions has a re-
quirement for hamartin binding. The recurrent 18-p de-
letion in exon 40 of TSC2 lies within the putative ra-
baptin-binding domain (Xiao et al. 1997). However,
demonstration of the binding of rabaptin by tuberin
awaits independent confirmation, and the pathogenic
mechanism of this mutation is unclear at present. We
and others (Wilson et al. 1996; van den Ouweland et
al. 1997; Au et al. 1998) have identified recurrent mis-
sense mutations within a short stretch of only 11 nu-
cleotides (1849–1859) of TSC2. This region does not
correspond to any currently recognized functional do-
main of tuberin, but the effects that these mutations have
on recently proposed roles of tuberin, including regu-
lation of G0/G1 to S phase transition (Soucek et al. 1997),
can now be assessed. In contrast, despite reports of large
numbers of single-base changes and small deletions and
insertions at the TSC1 locus, no clearly pathogenic mis-
sense mutations have been described, and it appears
likely that complete loss of hamartin—rather than more-
subtle disruption of specific roles—is usual in TSC1 as-
sociated disease.
Note added in proof.—Since this article was accepted
for publication, mutations have been identified in three
further sporadic cases, all at the TSC2 locus. These were
(i) an intragenic deletion of ∼5 kb in patient 165 (iden-
tified by long PCR), (ii) a deletion of 34 bp from a 34-
bp tandem repeat spanning the exon 38/intron 38
boundary in patient 112 (the same mutation has been
reported elsewhere, in a different patient with TSC
[Beauchamp et al. 1998]), and (iii) a deletion of exon
41 and the 3′ UTR of TSC2 and part of the 3′ UTR of
PKD1 in patient 115 (identified by long PCR).
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